Management of in-transit metastases from cutaneous malignant melanoma

British Journal of Surgery

Volumn 91, Issue 6, 2004, Pages 673-682

  Hayes, A J ^a   Clark, M A ^a   Harries, M ^a   Thomas, J M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; MELPHALAN; TAMOXIFEN; TEMOZOLOMIDE;

AMPUTATION; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARBON MONOXIDE LASER THERAPY; CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG TOLERABILITY; EXCISION; FATIGUE; HISTOPATHOLOGY; HUMAN; IN TRANSIT METASTASIS; LIMB PERFUSION; LOW LEVEL LASER THERAPY; MEDLINE; MELANOMA; METASTASIS; NAUSEA; PALLIATIVE THERAPY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN CANCER; SUBCUTANEOUS TISSUE; SURGICAL TECHNIQUE; TOXICITY; TREATMENT OUTCOME; VOMITING;

AMPUTATION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; LASER SURGERY; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SKIN NEOPLASMS; TERMINOLOGY;

EID: 2942550552     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4610     Document Type: Review

References (90)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
3. Hughes TM, A'Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg 2000; 87: 892-901.
4. Hughes TM, Thomas JM. Combined inguinal and pelvic lymph node dissection for stage III melanoma. Br J Surg 1999; 86: 1493-1498.
5. McCarthy WH. Melanoma: Margins for error - another view. Aust NZ J Surg 1002; 72: 304-306.
6. Heenan PJ, Ghaznawie M. The pathogenesis of local recurrence of melanoma at the primary excision site. Br J Plast Surg 1999; 52: 209-213.
7. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al. Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
8. Hart IR, Goode NT, Wilson RE. Molecular aspects of the metastatic cascade. Biochim Biophys Acta 1989; 989: 65-84.
9. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-188.
10. Cascinelli N, Bufalino R, Marolda R, Belli F, Nava M, Galluzzo D et al. Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986; 12: 175-180.
11. Kelly JW, Sagebiel RW, Calderon W, Murillo L, Dakin RL, Blois MS. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 1984; 200: 759-763.
12. Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997; 15: 1039-1051.
13. Singletary SE, Tucker SL, Boddie AW Jr. Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanoma. Cancer 1988; 61: 1437-1440.
14. Roses DF, Karp NS, Oratz R, Dubin N, Harris MN, Speyer J et al. Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet 1991; 172: 262-268.
15. Haffner AC, Garbe C, Burg G, Buttner P, Orfanos CE, Rassner G. The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2495 patients. Br J Cancer 1992; 66: 856-861.
16. Sutherland CM, Mather FJ, Krementz ET. Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion. Surg Gynecol Obstet 1987; 164: 111-118.
17. Karakousis CP, Temple DF, Moore R, Ambrus JL. Prognostic parameters in recurrent malignant melanoma. Cancer 1983; 52: 575-579.
18. Aitken DR, James AG, Carey LC. Local cutaneous recurrence after conservative excision of malignant melanoma. Arch Surg 1984; 119: 643-646.
19. Roses DF, Harris MN, Rigel D, Carrey Z, Friedman R, Kopf AW. Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983; 198: 65-69.
20. Urist MM, Balch CM, Soong S, Shaw HM, Milton GW, Maddox WA. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 1985; 55: 1398-1402.
21. Zeitels J, LaRossa D, Hamilton R, Synnestvedt M, Schultz D. A comparison of local recurrence and resection margins for stage I primary cutaneous malignant melanomas. Plast Reconstr Surg 1988; 81: 688-693.
22. Taylor BA, Hughes LE. A policy of selective excision for primary cutaneous malignant melanoma. Eur J Surg Oncol 1985; 11: 7-13.
23. Balch GM, Murad TM, Soong SJ, Ingalls AL, Richards PC, Maddox WA. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 1979; 43: 883-888.
24. Griffiths RW, Briggs JC. Incidence of locally metastatic ('recurrent') cutaneous malignant melanoma following conventional wide margin excisional surgery for invasive clinical stage I tumours: importance of maximal primary tumour thickness. Br J Surg 1986; 73: 349-353.
25. Eastwood J, Baker TG. Cutaneous malignant melanoma in West Yorkshire: II. A prospective study of recurrence and prediction of lymph nodal metastasis. Br J Cancer 1984; 50: 35-43.
26. Olsen G. Some views on the treatment of melanomas of the skin. Arch Chir Neerl 1970; 22: 79-90.
27. Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. Dermatol Surg 1995; 21: 285-290.
28. Coats J. On a case of multiple melanotic sarcoma, with remarks on the mode of growth and extension of such tumours. Glasgow Med J 1885; 24: 92-97.
29. Norris W. Eight Cases of Melanosis with Pathological and Therapeutic Remarks on That Disease. Longman, Brown, Green, Longman and Roberts: London, 1857.
30. Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet 1907; i: 996-1003.
31. Olsen G. The malignant melanoma of the skin. New theories based on a study of 500 cases. Acta Chir Scand Suppl 1966; 365: 1-222.
32. Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318: 1159-1162.
33. Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998; 14: 272-275.
34. Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89: 1495-1501.
35. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262-267; discussion 267-269.
36. Roberts DL, Anstey AV, Barlow RJ, Cox NH, Newton Bishop JA, Corrie PG et al. UK guidelines for the management of cutaneous melanoma. Br J Dermatol 2002; 146: 7-17.
37. Australian Cancer Network. Guidelines for the Management of Cutaneous Melanoma. Australian Cancer Network: Sydney, 1997.
38. Thomas JM, Newton-Bishop J, A'Hern R et al. Excision margins in high-risk melanoma. New Engl J Med 2004; 350: 757-766.
39. Heenan PJ. Melanoma: margins for error. Aust NZ J Surg 2002; 72: 300-303.
40. Balch CM. Surgical margins for melanoma: is 2 cm too much? Aust NZ J Surg 2002; 72: 251-252.
41. Kaplan I, Ger R, Sharon U. The carbon dioxide laser in plastic surgery. Br J Plast Surg 1973; 26: 359-362.
42. 2 laser surgery in melanoma patients. Br J Surg 1980; 67: 318-320.
43. Andrews AHJr, Caldarelli DD. Carbon dioxide laser treatment of metastatic melanoma of the trachea and bronchi. Ann Otol Rhitiol Laryngol 1981; 90: 310-311.
44. Morgan AH, Norris JW, Hicks JN. Palliative laser surgery for melanoma metastatic to the larynx: report of two cases. Laryngoscope 1985; 95: 794-797.
45. Waters RA, Clement RM, Thomas JM. Carbon dioxide laser ablation of cutaneous metastases from malignant melanoma. Br J Surg 1991; 78: 493-494.
46. Hill S, Thomas JM. Treatment of cutaneous metastases from malignant melanoma using the carbon-dioxide laser. Eur J Surg Oncol 1993; 19: 173-177.
47. Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996; 83: 509-512.
48. Lingam MK, McKay AJ. Carbon dioxide laser ablation as an alternative treatment for cutaneous metastases from malignant melanoma. Br J Surg 1995; 82: 1346-1348.
49. Briele HA, Djuric M, Jung DT, Mortell T, Patel MK, Das Gupta TK. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res 1985; 45: 1885-1889.
50. Creech O Jr, Krementz E. Techniques of regional perfusion. Surgery 1966; 60: 938-947.
51. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-910.
52. Mubarak SJ, Owen CA. Double-incision fasciotomy of the leg for decompression in compartment syndromes. J Bone Joint Surg (US) 1977; 59A: 184-187.
53. Stehlin JS Jr. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 1969; 129: 305-308.
54. Stehlin JS, Giovanella BC, de Ipolyi PD, Muenz LR, Anderson RF. Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975; 140: 339-348.
55. Klaase JM, Kroon BB, van Geel BN, Eggermont AM, Franklin HR, Hart GA. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 1994; 167: 618-620.
56. Rossi CR, Foletto M, Pilati P, Mocellin S, Lise M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 2002; 29: 400-409.
57. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002; 9; 127-136.
58. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18 832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16: 2906-2912.
59. Hochster H, Strawderman MH, Harris JE, Atkins MB, Oken M, Skeel RT et al. Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687). Anticancer Drugs 1999; 10: 245-248.
60. Bulman AS, Jamieson CW. Isolated limb perfusion with melphalan in the treatment of malignant melanoma. Br J Surg 1980; 67: 660-662.
61. Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR, Hart AA. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115; 39-45.
62. Di Filippo F, Calabro A, Giannarelli D, Carlini S, Cavaliere F, Moscarelli F et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63: 2551-2561.
63. Lejeune FJ, Deloof T, Ewalenko P, Fruhling J, Jabri M, Mathieu M et al. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Remits Cancer Res 1983; 86: 268-276.
64. Rossi CR, Foletto M, Vecchiato A, Alessio S, Menin N, Lise M. Management of cutaneous melanoma MO: state of the art and trends. Eur J Cancer 1997; 33: 2302-2312.
65. Aigner K, Hild P, Henneking K, Paul E, Hundeiker M. Regional perfusion with cis-platinum and dacarbazine. Recent Results Cancer Res 1983; 86: 239-245.
66. Vaglini M, Belli F, Marolda R, Prada A, Santinami M, Cascinelli N. Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities. Eur J Surg Oncol 1987; 13: 127-129.
67. Fraker DL. Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 1999; 36: 841-907.
68. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
69. Fenig E, Eidelevich E, Njuguna E, Katz A, Gutman H, Sulkes A et al. Role of radiation therapy in the management of cutaneous malignant melanoma. Am J Clin Oncol 1999; 22: 184-186.
70. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999; 44: 607-618.
71. Colvin MC. Antitumor alkylating agents. In Cancer Principles and Practice of Oncology (6th edn), De Vita VT Jr, Hellman S, Rosenberg SA (eds). Lippincott Williams and Wilkins: Philadelphia, 2001; 363-376.
72. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
73. Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 2002; 29: 413-426.
74. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-2751.
75. Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82: 1158-1162.
76. Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 1999; 17: 1884-1890.
77. Chiarion Sileni V, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti L et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 2001; 11: 189-196.
78. Zrada S, Laucius JF, Nathan F, Sato T, Mastrangelo MJ, Berd D. Complete remission of metastatic melanoma after treatment with the dartmouth regimen. Proc Am Soc Clin Oncol 2001; 20: 361a (Abstract 1439).
79. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994; 12: 1553-1560.
80. Atkins MB, Lee SM, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 2003; 22: 708 (Abstract 2847).
81. Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Brocker EB, Neumann C et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002; 86: 179-184.
82. Del Vecchio M, Bajetta E, Vitali M, Gattinoni L, Santinami M, Daponte A et al. Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts). Proc Am Soc Clin Oncol 2003; 22: 709 (Abstract 2849).
83. Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001; 84: 1036-1042.
84. Johnston SR, Constenla DO, Moore J, Atkinson H, A'Hern RP, Dadian G et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998; 77: 1280-1286.
85. Keilholz U, Punt CJ, Gore ME, Suciu S, Kruit W, Patel P et al. Dacarbazine, cisplatin and EFN-α2b with or without IL-2 in advanced melanoma: Final analysis of EORTC randomized phase III trial 18951. Proc Am Soc Clin Oncol 2003; 22: 708 (Abstract 2848).
86. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17: 968-975.
87. Merimsky O, Kollender Y, Inbar M, Lev-Chelouche D, Gutman M, Issakov J et al. Is forequarter amputation justified for palliation of intractable cancer symptoms? Oncology 2001; 60: 55-59.
88. Jaques DP, Coit DG, Brennan MF. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1989; 169: 1-6.
89. Dowsett C. Malignant fungating wounds: assessment and management. Br J Community Nurs 2002; 7: 394-400.
90. McMurray V. Managing patients with fungating malignant wounds. Nurs Times 2003; 99: 55-57.